CRDF
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.67 · operating margin -8256% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 721649 titres (~959793 USD)
- Insiders
- Mohindru ManiPACE GARY W
- Total bought
-
$959,793
Avg buy (VWAP, 90d window) $1.33 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-07-14
- Last synced
-
2026-08-04 10:23:03
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-14 | Mohindru Mani | Buy | 34,364 | $1.33 | $45,704 | Form 4 |
| 2026-07-14 | PACE GARY W | Buy | 687,285 | $1.33 | $914,089 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-08-03
CRDF presents a critically weak financial profile — persistent operating losses, high cash burn, and no meaningful revenue growth — that is not offset by a diluted catalyst signal.
The first sentence of the analysis written for CRDF on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Ebitda Margin | -7579.6% | -6592.5% | -8410.5% | -9965.8% | -7754.9% | |
| Operating Profit Margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% | |
| Pretax Profit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Continuous Operations Profit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Net Profit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Bottom Line Profit Margin | -7736.3% | -6655.2% | -8496.9% | -10033.2% | -7887.2% | |
| Current Ratio | 3.668 | 7.079 | 7.415 | 14.253 | 22.279 | |
| Quick Ratio | 3.668 | 7.079 | 7.415 | 14.253 | 22.279 | |
| Solvency Ratio | -2.725 | -3.162 | -3.450 | -3.906 | -3.050 | |
| Cash Ratio | 1.066 | 3.833 | 2.074 | 2.094 | 1.821 | |
| Price To Earnings Ratio | -4.072 | -4.568 | -1.591 | -1.573 | -8.233 | |
| Price To Earnings Growth Ratio | 0.149 | -2.124 | -0.354 | -0.072 | 0.254 | |
| Forward Price To Earnings Growth Ratio | 0.149 | -2.124 | -0.354 | -0.072 | 0.254 | |
| Price To Earnings Diluted Ratio | -4.072 | -4.568 | -1.591 | -1.573 | -8.233 | |
| Price To Earnings Diluted Growth Ratio | 0.149 | -2.124 | -0.354 | -0.072 | 0.254 | |
| Price To Book Ratio | 4.138 | 2.493 | 0.948 | 0.574 | 1.671 | |
| Price To Sales Ratio | 316.734 | 302.783 | 135.496 | 158.135 | 653.399 | |
| Price To Free Cash Flow Ratio | -4.947 | -5.475 | -2.101 | -1.758 | -10.091 | |
| Price To Operating Cash Flow Ratio | -4.953 | -5.486 | -2.141 | -1.805 | -10.181 | |
| Debt To Assets Ratio | 0.013 | 0.016 | 0.026 | 0.023 | 0.021 | |
| Debt To Equity Ratio | 0.018 | 0.018 | 0.031 | 0.026 | 0.022 | |
| Debt To Capital Ratio | 0.018 | 0.018 | 0.030 | 0.025 | 0.022 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.363 | 1.172 | 1.171 | 1.093 | 1.065 | |
| Working Capital Turnover Ratio | 0.009 | 0.009 | 0.006 | 0.003 | 0.003 | |
| Operating Cash Flow Ratio | -2.313 | -2.807 | -2.959 | -4.331 | -3.513 | |
| Operating Cash Flow Sales Ratio | -63.951 | -55.187 | -63.293 | -87.617 | -64.178 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.002 | 1.019 | 1.026 | 1.009 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -45.581 | -24.749 | -14.373 | -12.457 | -7.387 | |
| Capital Expenditure Coverage Ratio | -861.886 | -471.163 | -53.070 | -37.915 | -112.390 | |
| Dividend Paid And Capex Coverage Ratio | -861.886 | -471.163 | -53.070 | -25.896 | -100.611 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | -0.011 | -0.001 | |
| Enterprise Value Multiple | -3.809 | -3.484 | -1.136 | -1.232 | -8.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 0.0% |
| Ebit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Ebitda Margin | -7579.6% | ▼-987.1% | ▲481.1% |
| Operating Profit Margin | -8256.3% | ▼-1133.2% | ▲355.7% |
| Pretax Profit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Continuous Operations Profit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Net Profit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Bottom Line Profit Margin | -7736.3% | ▼-1081.1% | ▲425.5% |
| Current Ratio | 3.668 | ▼-3.411 | ▼-7.271 |
| Quick Ratio | 3.668 | ▼-3.411 | ▼-7.271 |
| Solvency Ratio | -2.725 | ▲0.437 | ▲0.534 |
| Cash Ratio | 1.066 | ▼-2.767 | ▼-1.112 |
| Price To Earnings Ratio | -4.072 | ▲0.496 | ▼-0.065 |
| Price To Earnings Growth Ratio | 0.149 | ▲2.273 | ▲0.578 |
| Forward Price To Earnings Growth Ratio | 0.149 | ▲2.273 | ▲0.578 |
| Price To Earnings Diluted Ratio | -4.072 | ▲0.496 | ▼-0.065 |
| Price To Earnings Diluted Growth Ratio | 0.149 | ▲2.273 | ▲0.578 |
| Price To Book Ratio | 4.138 | ▲1.645 | ▲2.173 |
| Price To Sales Ratio | 316.734 | ▲13.951 | ▲3.425 |
| Price To Free Cash Flow Ratio | -4.947 | ▲0.528 | ▼-0.072 |
| Price To Operating Cash Flow Ratio | -4.953 | ▲0.534 | ▼-0.040 |
| Debt To Assets Ratio | 0.013 | ▼-0.002 | ▼-0.006 |
| Debt To Equity Ratio | 0.018 | -0.000 | ▼-0.005 |
| Debt To Capital Ratio | 0.018 | -0.000 | ▼-0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.363 | ▲0.192 | ▲0.191 |
| Working Capital Turnover Ratio | 0.009 | ▲0.000 | ▲0.003 |
| Operating Cash Flow Ratio | -2.313 | ▲0.494 | ▲0.871 |
| Operating Cash Flow Sales Ratio | -63.951 | ▼-8.764 | ▲2.894 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.001 | ▼-0.010 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -45.581 | ▼-20.831 | ▼-24.671 |
| Capital Expenditure Coverage Ratio | -861.886 | ▼-390.724 | ▼-554.601 |
| Dividend Paid And Capex Coverage Ratio | -861.886 | ▼-390.724 | ▼-559.361 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▲0.002 |
| Enterprise Value Multiple | -3.809 | ▼-0.325 | ▼-0.255 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $187.8M | $206.8M | $66.1M | $61.0M | $234.6M | |
| Enterprise value | $171.2M | $156.9M | $46.6M | $47.4M | $225.7M | |
| EV / Sales | 288.68x | 229.65x | 95.53x | 122.82x | 628.82x | |
| EV / Op. cash flow | -4.51x | -4.16x | -1.51x | -1.40x | -9.80x | |
| EV / Free cash flow | -4.51x | -4.15x | -1.48x | -1.37x | -9.71x | |
| EV / EBITDA | -3.81x | -3.48x | -1.14x | -1.23x | -8.11x | |
| Net debt / EBITDA | 0.37x | 1.11x | 0.47x | 0.35x | 0.32x | |
| Current ratio | 3.67x | 7.08x | 7.42x | 14.25x | 22.28x | |
| Income quality | 0.83x | 0.83x | 0.74x | 0.87x | 0.81x | |
| Graham net-net | $1 | $2 | $1 | $2 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $43.7M | $81.6M | $67.0M | $103.5M | $139.6M | |
| Invested capital | $44.9M | $83.7M | $69.9M | $107.0M | $142.7M | |
| Return on assets | -74.1% | -46.7% | -50.8% | -33.3% | -18.9% | |
| Operating ROA | -61.6% | -54.4% | -45.9% | -30.0% | -20.3% | |
| Return on tangible assets | -74.1% | -46.7% | -50.8% | -33.3% | -18.9% | |
| Return on equity | -101.0% | -54.8% | -59.4% | -36.4% | -20.1% | |
| Return on invested capital | -105.9% | -57.6% | -63.2% | -36.6% | -20.1% | |
| Return on capital employed | -107.6% | -58.1% | -63.8% | -36.8% | -20.2% | |
| Earnings yield | -24.4% | -22.0% | -62.7% | -63.4% | -12.1% | |
| Free cash flow yield | -20.2% | -18.3% | -47.6% | -56.9% | -9.9% | |
| Capex / Op. cash flow | -0.1% | -0.2% | -1.9% | -2.6% | -0.9% | |
| Capex / Depreciation | 4.9% | 19.8% | 146.2% | 378.0% | 45.5% | |
| Capex / Sales | 7.4% | 11.7% | 119.3% | 231.1% | 57.1% | |
| SG&A / Sales | 2398.7% | 1827.5% | 2672.7% | 3414.8% | 3297.5% | |
| R&D / Sales | 5957.7% | 5395.6% | 6733.0% | 7022.5% | 4840.1% | |
| Stock comp / Sales | 960.0% | 696.9% | 924.0% | 1102.6% | 900.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 112d | 413d | 215d | 729d | 544d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 112d | 413d | 215d | 729d | 544d | |
| Cash conversion cycle | 112d | 413d | 215d | 729d | 544d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-9.2%EV / Sales ▲+25.7%EV / EBITDA ▼-9.3%EV / Op. cash flow ▼-0.353Earnings yield ▼-0.024
Profitability
Return on equity ▼-0.463Return on assets ▼-0.273Return on invested capital ▼-0.483Return on capital employed ▼-0.495Operating ROA ▼-0.071Income quality ▼-0.003Tax burden 0.000
Efficiency
Days sales outstanding ▼-301.073Days payables outstanding n/aOperating cycle ▼-301.073Cash conversion cycle ▼-301.073Capex / Sales ▼-0.043R&D / Sales ▲+5.621
Balance-sheet strength
Current ratio ▼-3.411Net debt / EBITDA ▼-0.739Working capital ▼-37892000.000Invested capital ▼-38752000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-19.9%EV / Sales ▼-54.1%EV / EBITDA ▲+53.0%EV / Op. cash flow ▲+5.284Earnings yield ▼-0.124
Profitability
Return on equity ▼-0.809Return on assets ▼-0.552Return on invested capital ▼-0.858Return on capital employed ▼-0.874Operating ROA ▼-0.413Income quality ▲+0.013Tax burden 0.000
Efficiency
Days sales outstanding ▼-431.918Days payables outstanding n/aOperating cycle ▼-431.918Cash conversion cycle ▼-431.918Capex / Sales ▼-0.497R&D / Sales ▲+11.176
Balance-sheet strength
Current ratio ▼-18.611Net debt / EBITDA ▲+0.053Working capital ▼-95834000.000Invested capital ▼-97805000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-07-15 Cardiff Oncology Announces $10 Million Registered Direct Offering SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per share and accompanying warrant in a registered direct offering. In addition, certain members of the Company''s officers and directors are participating in the offering and have entered into definitive agreements for the purchase and sale of an aggregate of 731,707 shares of the Company''s common stock and accompanying warrants to purchase up to an aggregate of 731,707 shares of the Company''s common stock, at a purchase price of $1.435 per share and accompanying warrant.
- 2026-06-03 Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript
- 2026-06-02 Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -
- 2026-06-01 Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.
- 2026-05-21 Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data
- 2026-05-20 Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday said that it filed a lawsuit against Nerviano Medical Sciences (NMS), disputing NMS''s claim that Cardiff materially breached their licensing agreement for onvansertib.
- 2026-05-14 Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial